U.S. State Department/PEPFAR Deal History & Licensing Activity
U.S. State Department/PEPFAR is a life sciences. Over the past three years, U.S. State Department/PEPFAR has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals).
Deals (12mo)
4
Active Trials
0
Top Modality
Small Molecules
Focus Area
Infectious Disease
U.S. State Department/PEPFAR Recent Deal Activity
Licensing, acquisition, and partnership transactions involving U.S. State Department/PEPFAR in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| lenacapavir | Gilead Sciences | Small Molecules | Approved | license | Mar 2026 |
| lenacapavir | Gilead | Small Molecules | Unknown | license | Sep 2025 |
U.S. State Department/PEPFAR Pipeline Focus
Therapeutic areas and modalities where U.S. State Department/PEPFAR is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches U.S. State Department/PEPFAR's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About U.S. State Department/PEPFAR Licensing & Deal Activity
U.S. State Department/PEPFAR is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, U.S. State Department/PEPFAR ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for U.S. State Department/PEPFAR include Infectious Disease (5 deals and trials). In terms of modality, U.S. State Department/PEPFAR has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for U.S. State Department/PEPFAR and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against U.S. State Department/PEPFAR's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.